Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease is a research paper published in Frontiers in Immunology (2022). On theSindex it has a DataRank of 0.464. It has been cited 21 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.464
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCATS NIH HHS
Grant: KL2 TR000455
National Institutes of Health
Grant: 2KL2TR000455-06
Atlanta Clinical and Translational Science Institute (ACTSI) Renewal
National Center for Advancing Translational Sciences
CURE Childhood Cancer
FWCI
2.60
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Additional file 1 of Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)